enGene (NasdaqCM:ENGN) FY Conference Summary Company Overview - enGene is a biotechnology company with a proprietary DDX platform, focusing on non-muscle invasive bladder cancer (NMIBC) treatment through its lead asset, detalimogene, a non-viral gene therapy [2][6]. Key Points Technology and Product Development - Detalimogene is currently in an open-label pivotal study, with plans for a data update at a scientific conference in Q2 2026 and long-term data sharing in the second half of 2026 [4][6]. - The company has over $300 million in cash, sufficient to fund operations until the second half of 2028 [6]. Market Opportunity - NMIBC is a significant market with approximately 740,000 cases in the U.S., and the bladder cancer market is projected to grow from $2 billion to over $20 billion due to new treatment paradigms [15][25]. - The treatment landscape is evolving, with a shift from traditional therapies (BCG and bladder removal) to new therapies that can be sequenced, as NMIBC is recognized as a slow-progressing disease [18][20]. Competitive Differentiation - Detalimogene is the only non-viral gene therapy in the market, offering advantages in efficacy, tolerability, and ease of use compared to existing treatments [27][30]. - The product can be stored in regular freezers and does not require special handling, making it more accessible for community urologists [30][32]. Go-to-Market Strategy - enGene plans to employ 40-60 sales representatives in the U.S. and is evaluating its strategy for Europe, considering partnerships for market entry [36][38]. - Targeting community practices, particularly those organized in LUGPAs, will be crucial for market penetration [36][40]. Clinical Trial Updates - The pivotal study, LEGEND, underwent significant protocol changes to align with standard care practices, including mandatory second resections for T1 patients and objective biopsy requirements [41][46]. - The FDA has been supportive, granting Fast Track, RMAT, and CDRP designations, which facilitate the development process [58][80]. Future Directions - Detalimogene's platform has potential applications beyond NMIBC, with ongoing cohorts for patients naive to BCG and those with papillary growths [75][76]. - The company is participating in the CDRP pilot program, which allows for early dialogue with the FDA regarding manufacturing processes [78][80]. Key Opinion Leader Feedback - Feedback indicates that while other products exist, they are not direct competitors due to differing efficacy rates and patient needs. Detalimogene is positioned to meet the specific requirements of community urologists [83][84]. Data Expectations - Upcoming data disclosures are anticipated to show a complete response (CR) rate within the 50%-70% range, with a preliminary CR rate of 63% noted previously [87][88]. - Tolerability is highlighted as a critical factor, with enGene reporting low discontinuation and treatment interruption rates compared to competitors [93][94]. Conclusion - enGene is poised for significant growth in the NMIBC market with its unique product offering and strategic approach to market entry and clinical development. The company’s focus on tolerability and ease of use positions it well against existing therapies, potentially transforming treatment paradigms in bladder cancer.

Company Overview - enGene Holdings Inc. (NASDAQ:ENGN) is focused on developing non-viral gene therapies for mucosal diseases, particularly in the bladder cancer treatment sector [4] - The company is headquartered in Saint-Laurent, Quebec, and was founded in 1999 [4] Clinical Development - enGene is advancing its lead candidate, detalimogene voraplasmid, into late-stage development for high-risk non-muscle invasive bladder cancer (NMIBC) [3] - A pivotal study is currently underway, with a key data update expected in the second half of 2026 [2] Financial Position - On January 21, enGene expanded its debt facility with Hercules Capital to up to $125 million, which includes $25 million immediately available for refinancing existing debt [3] - The additional financing of up to $100 million is tied to clinical, regulatory, and commercial milestones, enhancing the company's financial flexibility as it transitions to a potential commercial-stage entity [3] Investment Potential - enGene is viewed as a high-risk, high-reward investment opportunity due to its innovative approach and the potential for significant upside in the oncology market [4] - The company's strengthened liquidity and upcoming pivotal data position it favorably within a competitive landscape [4]

Summary of enGene Holdings Conference Call Company Overview - **Company**: enGene Holdings (NasdaqCM: ENGN) - **Focus**: Non-viral gene therapy for various diseases, specifically targeting non-muscle invasive bladder cancer (NMIBC) with its lead asset, detalimogene voraplasmid [1][2] Core Product Insights - **Lead Asset**: Detalimogene voraplasmid - **Indication**: Non-muscle invasive bladder cancer (NMIBC) - **Market Potential**: Projected to grow to over $20 billion due to a shift from an incident-based to a prevalent-based disease model [2] - **Efficacy and Tolerability**: Demonstrated promising efficacy and tolerability, with a focus on ease of use for both community and academic urologists [2][3] Market Dynamics - **Current NMIBC Statistics**: Approximately 730,000 cases in the U.S., with 65,000 new cases annually [3] - **Treatment Landscape**: Current management involves BCG therapy, which has been in chronic backorder and presents challenges in administration [4][5] - **Unmet Needs**: Significant unmet needs in the NMIBC market, particularly in community settings where most urologists practice [5][6] Competitive Advantages - **Non-Viral Approach**: Overcomes limitations of viral gene therapies, such as genetic payload size, redosing issues, and high manufacturing costs [3] - **Ease of Administration**: Detalimogene can be administered intravesically with minimal logistical requirements, making it suitable for community practices [12][14] - **Cost-Effectiveness**: Competitive cost of goods due to simple manufacturing processes [12][18] Clinical Development - **Pivotal Program**: Fully enrolled pivotal program for NMIBC patients unresponsive to BCG, with 125 patients enrolled [9] - **Efficacy Data**: Six-month complete response (CR) rate of 62%, showing improvement from pre-protocol rates [11][13] - **Tolerability Profile**: Mostly grade 1 or 2 adverse events, with low rates of dose interruptions (1.6%) and discontinuations (0.8%) [11][14] Future Outlook - **Regulatory Plans**: Anticipated filing with the FDA in the second half of next year, with potential approval in 2027 [2][19] - **Market Growth**: NMIBC market currently valued at approximately $2 billion, expected to grow significantly [18] - **Strategic Positioning**: Detalimogene is positioned to integrate into community urologist practices without disrupting existing workflows, offering a more patient-friendly treatment option [18][19] Conclusion - **Company's Financial Health**: Well-capitalized with over $100 million raised recently, providing a strong foundation for future growth and development [17][18] - **Commitment to Innovation**: enGene is focused on delivering effective and accessible treatments for NMIBC, aiming to improve patient outcomes and streamline urologist practices [16][19]

Summary of enGene Holdings Conference Call Company Overview - **Company**: enGene Holdings (NasdaqCM: ENGN) - **Focus**: Development of non-viral gene therapies for bladder cancer, specifically targeting non-muscle invasive bladder cancer (NMIBC) Industry Context - **Disease Prevalence**: NMIBC affects approximately 730,000 patients in the US, with about 85,000 new cases annually [1][2] - **Market Size**: The management of NMIBC is estimated to cost the healthcare system $6.5 billion per year [3] - **Current Treatment Landscape**: Traditional treatments include BCG therapy, IV chemotherapy, and radical cystectomy, which are often associated with high morbidity and mortality [4][5] Core Product Insights - **Product**: Detalimogene voraplasmid, a non-viral gene therapy designed for intravesical administration [7] - **Mechanism**: Combines plasmid DNA with RIG-I agonists and IL-12 to activate both innate and adaptive immune systems [7] - **Manufacturing**: Utilizes four simple ingredients, allowing for competitive cost of goods and easier handling [8] Clinical Development - **LEGEND Program**: Focused on BCG-unresponsive NMIBC patients, with 125 patients enrolled in the pivotal cohort [8][10] - **Efficacy Data**: - 63% complete response (CR) rate at any time for post-amendment patients [11] - 62% CR rate at six months, showing improvement over previous data [11][13] - **Tolerability**: 42% treatment-related adverse event rate, primarily mild and associated with catheterization [14][15] Competitive Landscape - **Comparison with Other Products**: Detalimogene's efficacy and tolerability are competitive with other approved products, such as those from J&J [18][19] - **Market Positioning**: Positioned as a first-line treatment option for busy community urologists, emphasizing ease of use and integration into practice [21][27] Regulatory and Future Outlook - **FDA Engagement**: Ongoing discussions with the FDA regarding clinical endpoints and potential approval timelines, with a target for filing in the second half of next year and potential approval in 2027 [21] - **Financial Position**: Company has sufficient cash reserves to support operations through 2027 [21] Additional Insights - **Community Urologist Feedback**: There is enthusiasm for new products, including J&J's TAR-200, which is expected to integrate well into existing treatment workflows [22][23] - **Importance of Durability**: While CR at any time is a primary endpoint, durability of response is also critical for treatment decisions, especially for older patients with multiple options [25][26] Conclusion - enGene Holdings is positioned to address significant unmet needs in the NMIBC market with its innovative non-viral gene therapy, which offers a competitive profile in terms of efficacy, tolerability, and ease of use for healthcare providers. The company is on track for potential regulatory approval and is well-prepared to capitalize on emerging market opportunities.

Summary of enGene Holdings Conference Call on DETALIMGENE Company Overview - **Company**: enGene Holdings (NasdaqCM: ENGN) - **Focus**: Development of DETALIMGENE, a non-viral gene therapy for high-risk BCG unresponsive non-muscle invasive bladder cancer (NMIBC) Key Points from the Conference Call Industry Context - **Target Disease**: High-risk BCG unresponsive NMIBC, particularly carcinoma in situ (CIS) - **Current Treatment Landscape**: Limited options for patients who progress to BCG unresponsive disease, with radical cystectomy being a last resort due to high morbidity and mortality rates [doc id='22'][doc id='23'] Clinical Trial Updates - **Enrollment**: Completion of enrollment in the pivotal cohort with 125 patients, exceeding the original target by 25% due to investigator demand [doc id='3'][doc id='4'] - **Protocol Amendments**: Significant changes made to align the trial with standard care, including re-resection requirements for T1 lesions and biopsy confirmations for persistent CIS [doc id='8'][doc id='9'] - **Efficacy Data**: - Six-month complete response (CR) rate increased to 62% post-amendment, compared to previous rates of 47% [doc id='4'][doc id='12'] - Anytime CR rate reported at 63% [doc id='10][doc id='14'] - High-risk patient characteristics noted, with 42% having concurrent papillary disease [doc id='10][doc id='41'] Safety and Tolerability - **Adverse Events**: 42% of patients experienced treatment-related adverse events, mostly mild (grade one or two) [doc id='17'] - **Discontinuation Rates**: Very low treatment discontinuation (0.8%) and interruption (1.6%) rates, indicating a favorable safety profile [doc id='17] Competitive Positioning - **Differentiation**: DETALIMGENE is positioned as a potentially best-in-class therapy due to its ease of use, tolerability, and competitive efficacy [doc id='5][doc id='30] - **Market Readiness**: Anticipation of high uptake among providers due to its non-viral nature and reduced logistical burdens compared to existing therapies [doc id='38][doc id='39] Future Outlook - **Regulatory Engagement**: Plans to engage with the FDA regarding the statistical analysis plan (SAP) and patient inclusion criteria for final analysis [doc id='15][doc id='36] - **Long-term Data**: Expectation of 12-month data availability in the second half of 2026, with a BLA filing planned for the same period [doc id='30][doc id='29] Insights from Clinical Experts - **Real-world Management**: Insights shared by Dr. Suzanne Merrill on the challenges of managing NMIBC and the importance of bladder-sparing therapies [doc id='20][doc id='23] - **Treatment Selection**: Emphasis on the need for individualized treatment strategies based on efficacy, safety, and logistical considerations [doc id='24][doc id='45] Conclusion - **Overall Sentiment**: Positive outlook on DETALIMGENE's potential to provide a new treatment option for NMIBC patients, with a focus on improving patient quality of life and reducing the burden on healthcare providers [doc id='30][doc id='27]

Summary of enGene Holdings FY Conference Call Company Overview - **Company**: enGene Holdings (NasdaqCM: ENGN) - **Focus**: Non-viral gene therapy utilizing the Dually Derivatized Oligochitosan (DDX) platform - **Lead Asset**: Detalimogene voraplasmid, targeting non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) resistant to Bacillus Calmette-Guérin (BCG) [2][3] Industry Context - **Bladder Cancer Statistics**: - Sixth most common cancer in the U.S. - Approximately 780,000 patients currently, with 82,000 new cases annually [5] - **Current Treatment Landscape**: - BCG is the standard treatment but is often on backorder, leading to radical cystectomy in many cases [5] Core Points and Arguments - **Efficacy and Tolerability**: - Detalimogene voraplasmid shows a 71% complete response (CR) rate with good tolerability [7][10] - Compared to existing products with CR rates of 20% to 40% [8] - **Ease of Administration**: - No pre-washes, special handling, or co-medications required, making it more suitable for busy community urology practices [9][10] - **Protocol Changes in LEGEND Study**: - Implemented three protocol amendments to enhance efficacy, including stricter enrollment criteria for T1 patients and allowing resection of TA [13][16] - **Regulatory Confidence**: - High confidence in the registrational path, supported by FDA engagement and recent designations [20] Competitive Landscape - **Differentiation from Competitors**: - Detalimogene voraplasmid is non-viral, contrasting with newer products that may require complex handling [11][12] - **Market Positioning**: - Targeting community urologists who may not be tracking new medications closely, focusing on the product's efficacy and ease of use [22] Future Outlook - **Clinical Development**: - Anticipated data updates in Q4 of the current year, with a BLA filing expected in mid-next year and potential approval in 2027 [28] - **Cash Position**: - Over $250 million in cash, sufficient to fund operations into 2027 [28] - **Expansion Beyond Bladder Cancer**: - Potential applications of the DDX platform in other cancers and mucosal delivery systems [26][27] Additional Insights - **AI Integration**: - enGene is exploring AI's potential to enhance drug development and commercialization processes [33][34] - **Regulatory Environment**: - Positive interactions with the FDA, indicating a supportive regulatory landscape for enGene's products [35][36] Conclusion - enGene Holdings is positioned to address significant unmet needs in bladder cancer treatment with its innovative non-viral gene therapy platform, demonstrating strong efficacy, tolerability, and ease of use, while maintaining a solid financial position and regulatory support for future growth.

Financial Data and Key Metrics Changes - The company reported a complete response (CR) rate of 71% in the September 2024 update, indicating a strong efficacy profile for detalimogene voraplasmid [3][9] - The target enrollment for the study has been reached at 100 patients, with expectations to exceed this number, which is a significant increase from the previous cohort of 21 patients [3][15] Business Line Data and Key Metrics Changes - The majority of patients enrolled in the study will be under the new protocol, which aligns with standard care practices, enhancing the profile of detalimogene voraplasmid [3][5] - The company is focusing on pivotal cohort 1 while also initiating additional cohorts to expand knowledge and data for treating urologists [19] Market Data and Key Metrics Changes - The company is preparing for a Biologics License Application (BLA) submission in the second half of 2026, indicating a strategic timeline for regulatory approval [15][16] - The company is confident in its manufacturing capabilities, which are crucial given the challenges faced in the industry [16] Company Strategy and Development Direction - The company aims to provide incremental data updates to enhance the understanding of detalimogene voraplasmid's efficacy and safety profile [3][9] - There is a strong emphasis on aligning the study protocols with standard care to improve the treatment profile and increase the likelihood of regulatory approval [10][15] Management's Comments on Operating Environment and Future Outlook - Management expressed excitement about reaching target enrollment and the potential for sharing more data in the future, which is expected to strengthen the company's position in the market [10][21] - The management highlighted the importance of understanding the heterogeneous nature of NMIBC patients when interpreting efficacy data [14] Other Important Information - The company has initiated three new cohorts to gather more data, focusing on different patient profiles, which will help in expanding the knowledge base for the treatment [19] - The management is cautious about making cross-study comparisons due to the small sample sizes and variability in patient characteristics [13][14] Q&A Session Summary Question: How many patients from the new protocol? - The vast majority of patients will be under the new protocol, with a target enrollment of 100 patients, likely to exceed this number [3] Question: Could you discuss the CR rate expectations? - The FDA has approved agents with CR rates between 20% to 40%, while the company reported a 71% CR rate, indicating confidence in the drug's efficacy [9] Question: What is the timeline for BLA filing? - The company updated its guidance for BLA submission to the second half of 2026, with strong regulatory and clinical teams ready to proceed [15][16] Question: Can you elaborate on the new cohorts? - The new cohorts aim to expand knowledge for treating urologists, with a focus on pivotal cohort 1 being the highest priority [19]